Deerfield Management Company, L.P. (Series C) Pharvaris N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Pharvaris N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,442,464 shares of PHVS stock, worth $57.5 Million. This represents 1.13% of its overall portfolio holdings.
Number of Shares
2,442,464
Previous 2,017,464
21.07%
Holding current value
$57.5 Million
Previous $35.5 Million
71.63%
% of portfolio
1.13%
Previous 0.82%
Shares
12 transactions
Others Institutions Holding PHVS
# of Institutions
81Shares Held
51MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY8.03MShares$189 Million7.09% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.78MShares$113 Million76.4% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.64MShares$109 Million78.75% of portfolio
-
Viking Global Investors LP3.65MShares$86 Million0.26% of portfolio
-
Eqt Fund Management S.A R.L.3.42MShares$80.6 Million4.59% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $795M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...